Expert Interview
Discussing the potential of Mainz Biomed's ColoAlert as an alternative to Cologuard for early detection of Precancerous Lesions and Colorectal Cancer.
Ticker(s): MYNZ, GH, EXASInstitution: Duke University
- Associate Professor of Medicine and GI Medical Oncologist at Duke University Medical Center
- Manages 30+ patients with Colon Cancer a year
- Research interest in Molecular Cancer Biology
Do you think the FDA will approve this based on the data so far?
On a scale of one to 10, how excited are you for this test?
Would you say that most of your patients are up-to-date with recommended screenings, or do you find that some patients are still non-compliant, or don't really do as you would like?
Is colonoscopy still the gold standard in your mind?
How does the ColoAlert compare to Cologuard?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
